EriVan Bio — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

EriVan Bio is a private, pre-revenue biotech company developing exosome-based research tools and therapeutic candidates. The company offers a portfolio of exosomes derived from adipose stem cells, bovine milk, and human plasma for research and biopharmaceutical manufacturing. With a leadership team combining scientific and entrepreneurial expertise, EriVan aims to advance exosome technology for targeted drug delivery, particularly in oncology, and diagnostics. Its foundation stems from award-winning academic research on miRNAs and extracellular vesicles.

OncologyImmunology

Technology Platform

Platform for the scalable production, engineering, and loading of exosomes from multiple sources (adipose stem cells, bovine milk, human plasma) for use as research tools, diagnostic biomarkers, and targeted therapeutic delivery vehicles, particularly for RNA-based drugs.

Opportunities

The global exosome market offers significant growth in research tools, diagnostics, and therapeutics.

EriVan's scalable production and multiple source materials position it well to capture share in the research supply segment.

The larger opportunity lies in leveraging exosomes as a superior, targeted delivery platform for RNA-based cancer therapies, a high-value area with strong pharma interest.

Risk Factors

Key risks include the technical challenges of consistent exosome engineering and manufacturing at clinical scale, high competition in the evolving exosome therapy space, dependence on future fundraising in a volatile capital market, and an uncertain regulatory pathway for exosome-based products.

Competitive Landscape

EriVan Bio competes in a rapidly growing field with numerous startups (e.g., Codiak BioSciences, Evox Therapeutics) and large pharma companies exploring exosome technology. Competition is based on production scalability, engineering capabilities, intellectual property, and therapeutic payload expertise. As a smaller, early-stage player, EriVan must differentiate through its specific source materials, cost-effective production, and strategic focus.

More companies in Biologics / Biosimilars →More companies in United States →